We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Prognostic Index Identifies Risk of Testicular Cancer Relapse

By LabMedica International staff writers
Posted on 02 Nov 2015
Print article
The Bond-Max automated immunostainer
The Bond-Max automated immunostainer (Photo courtesy of Leica Biosystems - Diagnostics Danaher)
The assessment of just three features can identify those at most at risk of relapse of a common kind of testicular cancer known as non-seminomatous germ cell tumor (NSGCT) even where there is no evidence of tumor spread.

Predicting who does or does not need chemotherapy is important in order to minimize treatment, with its undesirable side effects and a new test could be used in clinics to make decisions about which patients should be given chemotherapy. Patients diagnosed with testicular cancer in the early stages face a choice between monitoring with treatment, if relapse occurs, and moving directly on to chemotherapy with its associated long-term side effects.

Scientists at The Institute of Cancer Research (Sutton, UK) analyzed 177 tumor samples from patients with stage 1 non-seminomatous tumors, enrolled in clinical trials through the Medical Research Council (MRC) Clinical Trials Unit. Specifically these were patients diagnosed with stage I NSGCT (negative tumor markers and computer tomography scan confirming stage I) and enrolled post-operatively into a randomized study of two alternate imaging surveillance protocols.

Complete tumor cases were retrieved from each patient, and a full set of hematoxylin and eosin (H&E) sections from tumor for each case were examined by a board certified histopathologist. Sections were deparaffinized prior to immunochemical staining for C-X-C motif chemokine 12 (CXCL12) (R&D Systems; Minneapolis MN, USA). Antibodies were visualized using the Bond Polymer Refine Kit (Leica Biosystems; Newcastle, UK). Immunostaining was performed on the Leica Bond-Max automated immunostainer. To investigate CXCL12 as a marker for relapse prior to application to the clinical trial sample sets, the team first studied the tissue microarrays (TMA) representing 59 cases.

The tests were validated in an additional group of 80 patients. The vast majority of patients were in the low-risk group: 94.3% did not relapse in two years. In the moderate-risk group, 65.9% did not relapse. Strikingly, only 30% of patients did not relapse in the high-risk group. The authors concluded that CXCL12 and percentage embryonal carcinoma both stratify patients’ relapse risk over and above vascular invasion alone. This is anticipated to improve the stratification of patients and identify high-risk cases to be considered. The study was published on October 3, 2015, in the journal Clinical Cancer Research.

Related Links:

The Institute of Cancer Research
R&D Systems 
Leica Biosystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.